Celcuity upsizes senior secured facility to $500M, receives $30M immediate funding

Celcuity Inc.

Total facility increased to $500M ($350M committed + $150M discretionary); $30M funded, total outstanding $130M.
Adds $100M upon FDA approval of gedatolisib in 2L wild-type advanced breast cancer; $120M upon commercial milestones.
Maturity extended to Nov 1, 2029; interest-only period extended by 14 months, with possible 7-month FDA-approval extension.
Issued warrants for 50,537 shares to lenders; cashless exercise through tenth anniversary of Term D funding.
Funds will support NDA rolling submission via FDA's RTOR program, commercial launch prep, and strategic initiatives.

item 1.01item 2.03item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.